AUTHORS
Eitan Kugler, MD PhD, Alex Bataller, MD, PhD2, Kriti Gera, MD3, Farhad Ravandi, MD4, Najla Al Ali, MS5, Thura Win Htut, MD, FRCPath6, Guillermo Montalban-Bravo, MD7, Naval Daver, MD8, Courtney DiNardo, MD, MSCE9, Nicholas Short, MD10, Musa Yilmaz, MD11, David Sallman, MD12, Onyee Chan, MD13, Elias Jabbour, MD14, Jayastu Senapati, MBBS, MD, DM15, Alexandre Bazinet, MD, MSc16, Wei Ying Jen, BM BCh, FRCPath17, Ghayas C. Issa, MD18, Gautam Borthakur, MD19, Sherry Pierce, BSN, RN20, Jeffrey Lancet21, Guillermo Garcia-Manero, MD22, Hagop Kantarjian, MD23, Rami Komrokji, MD24, Tapan Kadia I, MD25
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
13 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Introduction
Venetoclax (Ven) combined with a hypomethylating agent (HMA) is a standard frontline therapy for older or intensive chemotherapy-ineligible patients with acute myeloid leukemia (AML). Treatment options after HMA-Ven failure remain limited, particularly in the absence of targetable mutations. Prior studies have reported a median overall survival (OS) of approximately 2 to 3 months after failure of HMA + VEN. In newly diagnosed AML, cladribine plus low-dose cytarabine (LDAC) and Ven (CLV) demonstrated a composite complete remission (CRc, defined as CR plus CR with incomplete count recovery) rate of 84% and a median OS of 52 months. Although small retrospective studies suggest that CLV can induce responses after HMA-Ven failure, the available cohorts were heterogeneous with respect to prior therapy and line of salvage. We therefore evaluated CLV as first salvage therapy in patients with AML who had received a single prior line of HMA-Ven.
Methods
We conducted a retrospective study at two comprehensive cancer centers of adults with AML who received HMA-Ven as frontline therapy followed by CLV as first salvage therapy between 2019 and 2026. Patients with therapy-related AML, prior treatment for an antecedent hematologic malignancy, or frontline HMA-Ven combined with an additional agent were excluded. Treatment consisted of cladribine 5 mg/m2 on days 1 to 5, LDAC 20 mg twice daily on days 1 to 10, and Ven on days 1 to 21 (100 to 400mg, dose adjusted for azoles). In responders receiving additional cycles, Ven was reduced to 7 days. Outcomes included CRc rate, duration of response (DOR), and OS measured from CLV day 1.
Results
Twenty-eight patients were included. The median duration of frontline HMA-Ven was 6 months (range, 1 - 37). Best response to frontline HMA-Ven was CRc in 16 patients (57%), MLFS in 3 (11%), and no response in 9 (32%). By the 2024 ELN classification applied at diagnosis, 16 patients (57%) were favorable, 6 (21%) intermediate, and 6 (21%) adverse risk. Median age at day 1 of salvage CLV was 77 years (range, 59 to 88). Five patients (18%) had untreated antecedent MDS. Karyotype was diploid in 11 patients (39%) and complex in 9 (32%). ECOG performance status was 0 or 1 in 21 patients (75%). The most frequent mutations were TET2 (41%), DNMT3A (30%), SRSF2 (22%), TP53 (22%), and NRAS/KRAS (26%). All 6 patients with TP53-mutated AML had a complex karyotype. The median number of CLV cycles was 1 (range, 1 - 7).
The overall CRc rate was 36% (10/28), median DOR 5.0 months (95% CI, 3.9 - not reached), and median OS 5.2 months (95% CI, 3.9 - 8.8). Four patients (14%) died before response assessment. Both response and survival were significantly associated with TP53 status: CRc rates were 45% versus 0% and median OS 6.2 versus 2.4 months for TP53-wild-type versus TP53-mutated patients (p<0.001), respectively. When karyotype was incorporated, patients with TP53-wild-type, non-complex karyotype AML (n=19/28) had a CRc rate of 47% and median OS of 7.6 months, compared with 11% and 3.1 months, respectively, in those with TP53 mutation and/or complex karyotype (n=9/28, p<0.001). Within the TP53-wild-type, non-complex subgroup, patients with NRAS/KRAS-wild-type disease (n=13/19) had a CRc rate of 62% and median OS of 15.7 months, versus 17% and 4.9 months, respectively, in those with NRAS/KRAS mutations (n=6/19, p<0.01).
Outcomes did not differ significantly by prior response to frontline HMA-Ven. Responders versus nonresponders had CRc rates of 37% versus 33% and median OS of 6.2 versus 4.0 months (p=0.69), respectively. Notably, 3 of 7 TP53-wild-type patients (43%) with primary refractory disease to HMA-Ven achieved CRc. Duration of prior HMA-Ven exposure greater than versus less than 5.6 months (cohort median) was associated with numerically but not statistically better outcomes (CRc 43% versus 29%, median OS 8.1 versus 3.6 months, p=0.1). No patient proceeded to allogeneic stem cell transplantation.
Conclusions
Outcomes with CLV as first salvage therapy after HMA-Ven failure were poor overall. However, patients with TP53-wild-type, non-complex karyotype, and particularly those with NRAS/KRAS-wild-type AML had encouraging outcomes, with a CRc rate of 62% and median OS of 15.7 months. CLV may therefore represent a reasonable salvage option for a molecularly selected subgroup. These findings warrant validation in larger and prospective cohorts.
DISCLOSURES
Eitan Kugler, MD PhD: No relevant conflicts of interest to declare.